Detalles de la búsqueda
1.
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Ann Hematol
; 102(3): 547-561, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36695874
2.
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Ann Hematol
; 100(9): 2387-2398, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34232360
3.
Correction to: Allogeneic hematopoietic stem cell transplantation improves longterm outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Ann Hematol
; 100(11): 2877-2878, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529106
4.
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
J Cancer Res Clin Oncol
; 141(11): 2013-22, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25976868
5.
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
J Cancer Res Clin Oncol
; 140(11): 1947-56, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24942335
Resultados
1 -
5
de 5
1
Próxima >
>>